The Experts below are selected from a list of 42 Experts worldwide ranked by ideXlab platform
Velickova Nevenka - One of the best experts on this subject based on the ideXlab platform.
-
Drugs may contribute oral-facial clefts in newborn baby
2011Co-Authors: Velickova Nevenka, Gacova Marina, Kamcev Nikola, Angelovska Bistra, Dimova CenaAbstract:Intruduction: A cleft is a gap in a body structure that results from incomplete closing of a specific structure during development. Clefts that occur in the lip and palate (roof of the mouth) are called oral-facial clefts. These birth defects occur very early in fetal development. The causes of these birth defects are not well understood. Cleft lips and palates are caused by a combination of genetic and environmental factors. Studies suggest that a number of genes, as well as environmental factors can cause oral-facial clefts. The aim of this study was to evaluate the risks factors, incidence, causes and symptoms of oral facial clefts at the children hospitalized in the children’s ward in Stip. This researches offer a preventive possibility to reduce appearance of oral-facial clefts in newborn baby. Material and methods: After birth, cleft lip and palate were diagnosed by physical exam. The risks factors and special exposure of their mothers during pregnancy were assessed. Also, the incidence, causes and symptoms at the children with oral facial clefts were evaluated. Their parents did n’t have oral-facial clefts. Results: The results indicated that during past 10 year children with oral facial clefts were borned in series in the same or closer month in the year (in the summer and the autumn). Also, was find that every year increased the number of children with oral-facial clefts and they were not associated with other syndrome. Children with oral-facial clefts have special problems and complication like feeding difficulties, ear infections and hearing loss. Conclusion: The obtain results suggest that environmental factors, such as drugs (including several different anti-seizure drugs) and maternal smoking, are risk factors for appearance of oral-facial clefts. We concluded that seasonal causes (such as pesticide exposure); maternal diet and vitamin intake; retinoids, which are members of the vitamin A family; anticonvulsant drugs; alcohol; cigarette use; nitrate compounds; organic solvents; parental exposure to lead; as teratogens increase the possibility of clefting. An increased risk for isolated oral-facial clefts was found in cases born to mothers treated with amoxicillin, phenytoin, oxprenolol, and Thiethylperazine during the second and third month of pregnancy, which is the critical period for during fetal development
-
Drugs like risks factors for oral-facial clefts in newborn baby
2011Co-Authors: Velickova NevenkaAbstract:Intruduction: A cleft is a gap in a body structure that results from incomplete closing of a specific structure during development. Clefts that occur in the lip and palate (roof of the mouth) are called oral-facial clefts. These birth defects occur very early in fetal development. The causes of these birth defects are not well understood. Cleft lips and palates are caused by a combination of genetic and environmental factors. Studies suggest that a number of genes, as well as environmental factors can cause oral-facial clefts. The aim of this study was to evaluate the risks factors, incidence, causes and symptoms of oral facial clefts at the children hospitalized in the children’s ward in Stip. This researches offer a preventive possibility to reduce appearance of oral-facial clefts in newborn baby. Material and methods: After birth, cleft lip and palate were diagnosed by physical exam. The risks factors and special exposure of their mothers during pregnancy were assessed. Also, the incidence, causes and symptoms at the children with oral facial clefts were evaluated. Their parents did n’t have oral-facial clefts. Results: The results indicated that during past 10 year children with oral facial clefts were borned in series in the same or closer month in the year (in the summer and the autumn). Also, was find that every year increased the number of children with oral-facial clefts and they were not associated with other syndrome. Children with oral-facial clefts have special problems and complication like feeding difficulties, ear infections and hearing loss. Conclusion: The obtain results suggest that environmental factors, such as drugs (including several different anti-seizure drugs) and maternal smoking, are risk factors for appearance of oral-facial clefts. We concluded that seasonal causes (such as pesticide exposure); maternal diet and vitamin intake; retinoids, which are members of the vitamin A family; anticonvulsant drugs; alcohol; cigarette use; nitrate compounds; organic solvents; parental exposure to lead; as teratogens increase the possibility of clefting. An increased risk for isolated oral-facial clefts was found in cases born to mothers treated with amoxicillin, phenytoin, oxprenolol, and Thiethylperazine during the second and third month of pregnancy, which is the critical period for during fetal development
J J Barriga - One of the best experts on this subject based on the ideXlab platform.
-
the antiemetic efficacy of Thiethylperazine and methylprednisolone versus Thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy fluorouracil doxorubicin and cyclophosphamide a randomized double blind cross over tri
Acta Oncologica, 1991Co-Authors: Eduardo Diazrubio, Miguel Martin, Rafael Rosell, J J Valerdi, J L Gonzalezlarriba, J J BarrigaAbstract:Forty-six women with breast cancer treated with adjuvant FAC (fluorouracil, doxorubicin and cyclophosphamide) entered a multicenter, randomized, double-blind, cross-over trial in which Thiethylperazine (T) (6.5 mg p.0 every 8 h x 3 days) plus methylprednisolone (MP) (250 mg i.v. x 2 doses) was compared with Thiethylperazine plus placebo. Forty-four patients were evaluable for efficacy. T + MP was significantly better in reducing vomiting (p < 0.01) and nausea (p < 0.02). The complete protection rate against vomiting was 36% for T + MP compared to 18% for T + placebo, and the percentage of nausea grades 0 + 1 (none or slight) was 59% and 27% respectively. The patient preference after cross-over was strikingly in favor of T + MP (70% versus 13%) (p < 0.001). The most important side-effects of T + MP were facial flushing (22%) and euphoria (27%). Other side-effects, such as dryness of the mouth and sedation, were common after both treatments. In conclusion, the study suggested that T + MP is superior to T alone in protecting from nausea and vomiting induced by FAC.
Raimo Sulkava - One of the best experts on this subject based on the ideXlab platform.
-
Thiethylperazine and tardive dyskinesia
Acta neurologica Scandinavica, 2009Co-Authors: Raimo SulkavaAbstract:Over a 14-month period in the outpatient department of a geriatric hospital, 7 female patients over 75 years of age were identified with tardive dyskinesia associated with the use of Thiethylperazine. The indication for Thiethylperazine treatment had been vertigo or dizziness. 3 of the patients also had symptoms related to cerebral arteriosclerosis and 2 had mild Parkinson's disease without levodopa therapy. None of them were markedly demented nor had chronic psychosis. Tardive dyskinesia appeared after a treatment period of 3 weeks to 6 years. These findings suggest that association of tardive dyskinesia with the use of Thiethylperazine is not uncommon in geriatric outpatients.
Dimova Cena - One of the best experts on this subject based on the ideXlab platform.
-
Drugs may contribute oral-facial clefts in newborn baby
2011Co-Authors: Velickova Nevenka, Gacova Marina, Kamcev Nikola, Angelovska Bistra, Dimova CenaAbstract:Intruduction: A cleft is a gap in a body structure that results from incomplete closing of a specific structure during development. Clefts that occur in the lip and palate (roof of the mouth) are called oral-facial clefts. These birth defects occur very early in fetal development. The causes of these birth defects are not well understood. Cleft lips and palates are caused by a combination of genetic and environmental factors. Studies suggest that a number of genes, as well as environmental factors can cause oral-facial clefts. The aim of this study was to evaluate the risks factors, incidence, causes and symptoms of oral facial clefts at the children hospitalized in the children’s ward in Stip. This researches offer a preventive possibility to reduce appearance of oral-facial clefts in newborn baby. Material and methods: After birth, cleft lip and palate were diagnosed by physical exam. The risks factors and special exposure of their mothers during pregnancy were assessed. Also, the incidence, causes and symptoms at the children with oral facial clefts were evaluated. Their parents did n’t have oral-facial clefts. Results: The results indicated that during past 10 year children with oral facial clefts were borned in series in the same or closer month in the year (in the summer and the autumn). Also, was find that every year increased the number of children with oral-facial clefts and they were not associated with other syndrome. Children with oral-facial clefts have special problems and complication like feeding difficulties, ear infections and hearing loss. Conclusion: The obtain results suggest that environmental factors, such as drugs (including several different anti-seizure drugs) and maternal smoking, are risk factors for appearance of oral-facial clefts. We concluded that seasonal causes (such as pesticide exposure); maternal diet and vitamin intake; retinoids, which are members of the vitamin A family; anticonvulsant drugs; alcohol; cigarette use; nitrate compounds; organic solvents; parental exposure to lead; as teratogens increase the possibility of clefting. An increased risk for isolated oral-facial clefts was found in cases born to mothers treated with amoxicillin, phenytoin, oxprenolol, and Thiethylperazine during the second and third month of pregnancy, which is the critical period for during fetal development
Eduardo Diazrubio - One of the best experts on this subject based on the ideXlab platform.
-
the antiemetic efficacy of Thiethylperazine and methylprednisolone versus Thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy fluorouracil doxorubicin and cyclophosphamide a randomized double blind cross over tri
Acta Oncologica, 1991Co-Authors: Eduardo Diazrubio, Miguel Martin, Rafael Rosell, J J Valerdi, J L Gonzalezlarriba, J J BarrigaAbstract:Forty-six women with breast cancer treated with adjuvant FAC (fluorouracil, doxorubicin and cyclophosphamide) entered a multicenter, randomized, double-blind, cross-over trial in which Thiethylperazine (T) (6.5 mg p.0 every 8 h x 3 days) plus methylprednisolone (MP) (250 mg i.v. x 2 doses) was compared with Thiethylperazine plus placebo. Forty-four patients were evaluable for efficacy. T + MP was significantly better in reducing vomiting (p < 0.01) and nausea (p < 0.02). The complete protection rate against vomiting was 36% for T + MP compared to 18% for T + placebo, and the percentage of nausea grades 0 + 1 (none or slight) was 59% and 27% respectively. The patient preference after cross-over was strikingly in favor of T + MP (70% versus 13%) (p < 0.001). The most important side-effects of T + MP were facial flushing (22%) and euphoria (27%). Other side-effects, such as dryness of the mouth and sedation, were common after both treatments. In conclusion, the study suggested that T + MP is superior to T alone in protecting from nausea and vomiting induced by FAC.